• Exelixis Inc., of South San Francisco, said it initiated a Phase II trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) vs. abiraterone/prednisone in patients with castration-resistant prostate cancer (CRPC) who have bone metastases and have not been previously treated with chemotherapy.